HIVe Home
HIV VACCINE ELECTRONIC (E) RESOURCE
Posted: 31 Oct 2011
Development and improvement of ELISPOT assays Internship-Leiden, The Netherlands
Apply Here
T cell immunity
Crucell

Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge.

Innovation is the drive force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology.

Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel & endemic and respiratory fields. 

The combination of our innovative technologies and creative minds drives Crucell’s success, which we measure in human and business terms. 

Johnson & Johnson completed the tender offer for Crucell N.V. (Crucell) on 22nd February 2011 and declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.

Headquartered in Leiden, the Netherlands, Crucell currently employs 1400 people and has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK the USA and Vietnam.


http://www.crucell.com/About_us

DETAILS

Department/Project:

Clinical Assays

 

Job Description:

First clinical trails have been started evaluating Crucells Malaria vaccine. At the Clinical Assays department T-cells directed against the Malaria protein present in the vaccine are enumerated with the ELISPOT assay to investigate the effect of the vaccine. 

In this internship two subjects will be addressed. First, a new ELISPOT will be developed to evaluate the T-cell responses towards the vaccine.

Second, stability of peptides in different storage formats will be investigated. To improve our existing ELISPOT assays the effect of peptide storage on the T-cell responses will be examined. Some aminoacids in the peptide sequences are very vulnerable to degradation, but it is not known if this will affect the T-cell responses.

ELIGIBILITY

Minimum Qualifications:

32-40 hours per week during 6 months or longer
Master student or final stage Bachelor student.
Fluent in English speaking, reading and writing.
Affinity with Immunology.
Preferably experience with Cellular Immunity Assays, such as Elispot.

Competences:
Accurate and precise
Flexible
Critical attitude towards him/herself

As part of Crucell's recruitment policy, a pre-employment screening will take place during the recruitment process.

CONTACT

For more information contact:

Hester van Zeeburg PhD (Scientist Clinical Assays) Hester.vanZeeburg@crucell.com, 071-519 7599

To send an application, use the "Apply here" button above or send your short letter of motivation and CV to:

Human Resources
P.O. Box 2048
2301 CA Leiden
stage@crucell.com